CN-121987673-A - Use of lactobacillus johnsonii or extracellular vesicles derived therefrom in the manufacture of a medicament for the treatment and/or prevention of degenerative scoliosis in adults

Abstract

The invention discloses application of lactobacillus johnsonii or extracellular vesicles derived from lactobacillus johnsonii in preparation of a medicament for treating and/or preventing adult degenerative scoliosis. Experiments prove that the extracellular vesicles from lactobacillus johnsonii can promote synthesis of nucleus pulposus extracellular matrix (ECM) from Adult Degenerative Scoliosis (ADS) and inhibit ECM degradation, effectively reverse nucleus pulposus ECM metabolic abnormality in the ADS progress process, and indicate that the nucleus pulposus extracellular vesicles can improve ADS disease progress by regulating and controlling the nucleus pulposus ECM metabolism.

Inventors

• WANG HUA
• ZHOU JIANGHONG
• Chen Huanxiong
• XU HAIXIA
• WANG WENBO
• TANG SANQUAN

Assignees

• 海南医科大学(海南省医学科学院)

Dates

Publication Date

20260508

Application Date

20260408

Claims (10)

1. 1. Use of lactobacillus johnsonii or extracellular vesicles derived therefrom for the manufacture of a medicament for the treatment and/or prophylaxis of degenerative scoliosis in adults.
2. 2. Use according to claim 1, in the preparation of a medicament for the treatment and/or prevention of disc degeneration.
3. 3. The use according to claim 1, in the preparation of a medicament for promoting synthesis of the extracellular matrix of the nucleus pulposus.
4. 4. The use according to claim 1, in the preparation of a medicament for inhibiting degradation of the extracellular matrix of the nucleus pulposus.
5. 5. The use according to claim 1, for the preparation of a medicament for up-regulating the COL2A1 gene, ACAN gene.
6. 6. The use according to claim 1, characterized by the use in the preparation of a medicament for down-regulating COL10A1 gene, MMP13 gene, ADSMTS gene.
7. 7. Use of lactobacillus johnsonii or extracellular vesicles derived therefrom for the manufacture of a medicament for the treatment and/or prevention of disc degeneration.
8. 8. Use of lactobacillus johnsonii or extracellular vesicles derived therefrom for the preparation of a medicament for modulating genes associated with extracellular matrix metabolism, wherein the modulating genes associated with extracellular matrix metabolism comprises up-regulating COL2A1 genes, up-regulating ACAN genes and down-regulating COL10A1 genes, down-regulating MMP13 genes, down-regulating ADSMTS genes.
9. 9. A pharmaceutical composition for the treatment and/or prevention of degenerative scoliosis or disc degeneration in adults, characterized in that it comprises lactobacillus johnsonii or extracellular vesicles derived therefrom as active substance.
10. 10. A pharmaceutical composition for regulating genes related to extracellular matrix metabolism, comprising lactobacillus johnsonii or extracellular vesicles derived therefrom as an active substance.

Description

Use of lactobacillus johnsonii or extracellular vesicles derived therefrom in the manufacture of a medicament for the treatment and/or prevention of degenerative scoliosis in adults Technical Field The invention belongs to the technical field of biological medicine, and particularly relates to application of lactobacillus johnsonii or extracellular vesicles derived from the lactobacillus johnsonii in preparation of a medicament for treating and/or preventing adult degenerative scoliosis. Background Adult degenerative scoliosis (Adult Degenerative Scoliosis, ADS) is a degenerative spinal disease with scoliosis as the main clinical manifestation, and the diagnostic criteria is a coronal Cobb angle greater than 10 °. In the onset of ADS, the spine is subject to non-physiological load distribution resulting in structural imbalance, deformity and progressive exacerbation, which not only compromises the functional integrity of the spine, but also has a significant negative impact on the overall health status of the patient. Currently, clinical treatments for ADS include two broad categories, conservative and surgical treatments. Conservative treatments encompass methods of pain relief medication, exercise therapy, physical therapy, and brace protection. Surgical intervention is a necessary option when patients have neurological deficit, spinal instability, or progressive deformity. However, the existing treatment schemes have obvious limitations that the conservative treatment effect is limited and the radical cure of the disease can not be realized, and the operation treatment can improve the deformity, but serious postoperative complications are accompanied by high invasiveness and high blood loss risk. In view of this, there is a need to develop new and effective means of pharmaceutical intervention to achieve the delay of ADS disease progression and thus the treatment of ADS. The pathogenesis of ADS is considered to be a combination of six etiologies, the core pathogenesis of which is an asymmetric degeneration of the disc, and the initial cause of such degeneration is lesions of the nucleus pulposus. The disc is composed of three parts at the anatomic level, the nucleus pulposus core, the outer annulus fibrosis and the cartilage end plates, where the nucleus pulposus maintains disc integrity by secreting extracellular matrix (ECM) components such as aggrecan, type II collagen and type X collagen. Decreased cellular activity and decreased numbers in the nucleus pulposus tissue can lead to abnormal ECM metabolism, cell proliferation and cytokine secretion of the disc, which in turn can lead to disc degeneration, one of the main pathological features of degenerative disc disease. Degeneration of the disc appears to be an irreversible process, whose avascular, non-neural nature limits its nutrient transport and cell density, and repair of the disc is particularly difficult. Gut Microorganisms (GM) have been identified as important co-occurrence partners for maintaining animal and human health. The probiotic lactobacillus johnsonii (Lactobacillus johnsonii, l. Johnsonii) is a potentially beneficial bacterium involved in the regulation of metabolic-related disorders, but it has not been reported whether it can alleviate ADS-related symptoms. Intestinal microbiota production metabolites or extracellular vesicles (extracellular vesicles, EVs) have been identified as important mediators of communication between intestinal microbiota and hosts. The intestinal-derived EVs can easily diffuse through mucous membranes or matrix and migrate directly into other tissues or immune cells, thereby participating in host pathophysiology regulation. Disclosure of Invention In view of the above technical problems, the present invention provides an application of lactobacillus johnsonii or extracellular vesicles derived from the same in preparing a medicament for treating and/or preventing adult degenerative scoliosis. In order to achieve the above purpose, the technical scheme adopted by the invention is as follows: in one aspect, the invention provides the use of lactobacillus johnsonii or extracellular vesicles derived therefrom in the manufacture of a medicament for the treatment and/or prophylaxis of degenerative scoliosis in adults. Preferably, the use in the manufacture of a medicament for the treatment and/or prevention of disc degeneration. Preferably, the use in the manufacture of a medicament for promoting synthesis of the extracellular matrix (ECM) of the nucleus pulposus. Preferably, the use in the manufacture of a medicament for inhibiting degradation of the extracellular matrix (ECM) of the nucleus pulposus. Preferably, the application in preparing medicines for up-regulating COL2A1 genes and ACAN genes. Preferably, the application in preparing medicines for down-regulating COL10A1 genes, MMP13 genes and ADSMTS genes. In yet another aspect, the invention provides the use of lactobacillus johnsonii or extracellular ves